On April 28, 2023 Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen Biotech"), an innovation-driven biopharmaceutical company, and Yantai MabPlex International Ltd. (hereinafter referred to as "MabPlex"), a global CDMO service provider, jointly reported a strategic collaboration agreement with regard to Sumgen’s SG301 in Yantai (Press release, Sumgen Biotech, APR 28, 2023, View Source;a=nav&id=347 [SID1234656266]). According to the agreement, MabPlex will integrate its internal resources to coordinate with the clinical and commercial developmentalignment of SG301, providing formulated solutions including manufacturing and process characterization & validation of batches during pivotal clinical studiesand mass production after NDA/BLA approval.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Shiwei Miao, co-founder of Sumgen Biotech, and Dr. Xinfang Li, CEO of MabPlex, along with representatives from both parties, attended the signing ceremony.
Dr. Shiwei Miao, co-founder of Sumgen Biotech, stated: "MabPlex is an important partner for Sumgen Biotech. Over the past three years of collaboration, MabPlex has assisted Sumgen Biotech in completing IND applications and early-stageclinical sample production for five antibody/ADC candidates, including SG301, SG2501, SG1906, SG301SC, and SG2918. MabPlex’s professional and compliant technical capabilities, along with their efficient and customer-centric service philosophy, have left a profound impression on the Sumgen team. We appreciate the efforts of the MabPlex team! Sumgen Biotech has always adhered to a development strategy of win-win cooperation, actively exploring innovative treatment solutions to ensure that patients worldwide can access affordable biopharmaceuticals of international standards. This strategic collaboration marks another significant step forward in the commercial development process of the SG301 ."
Dr. Xinfang Li, CEO of MabPlex, stated: "We appreciate the trust from Sumgen Biotech! As a comprehensive CDMO service provider, MabPlex remains committed to contributing to the global biopharmaceutical development. We wish the projects of Sumgen Biotech smooth progress in clinical research and hope they can provide new treatment options for more cancer patients soon."